Cited 0 time in
Genome Editing in Stem Cells for Disease Therapeutics
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Song, Minjung | - |
| dc.contributor.author | Ramakrishna, Suresh | - |
| dc.date.accessioned | 2022-07-12T00:49:30Z | - |
| dc.date.available | 2022-07-12T00:49:30Z | - |
| dc.date.created | 2021-05-12 | - |
| dc.date.issued | 2018-04 | - |
| dc.identifier.issn | 1073-6085 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/150254 | - |
| dc.description.abstract | Programmable nucleases including zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindrome repeats (CRISPR)/CRISPR-associated protein have tremendous potential biological and therapeutic applications as novel genome editing tools. These nucleases enable precise modification of the gene of interest by disruption, insertion, or correction. The application of genome editing technology to pluripotent stem cells or hematopoietic stem cells has the potential to remarkably advance the contribution of this technology to life sciences. Specifically, disease models can be generated and effective therapeutics can be developed with great efficiency and speed. Here we review the characteristics and mechanisms of each programmable nuclease. In addition, we review the applications of these nucleases to stem cells for disease therapies and summarize key studies of interest. | - |
| dc.language | 영어 | - |
| dc.language.iso | en | - |
| dc.publisher | HUMANA PRESS INC | - |
| dc.title | Genome Editing in Stem Cells for Disease Therapeutics | - |
| dc.type | Article | - |
| dc.contributor.affiliatedAuthor | Ramakrishna, Suresh | - |
| dc.identifier.doi | 10.1007/s12033-018-0072-9 | - |
| dc.identifier.scopusid | 2-s2.0-85042903653 | - |
| dc.identifier.wosid | 000427745000010 | - |
| dc.identifier.bibliographicCitation | MOLECULAR BIOTECHNOLOGY, v.60, no.4, pp.329 - 338 | - |
| dc.relation.isPartOf | MOLECULAR BIOTECHNOLOGY | - |
| dc.citation.title | MOLECULAR BIOTECHNOLOGY | - |
| dc.citation.volume | 60 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 329 | - |
| dc.citation.endPage | 338 | - |
| dc.type.rims | ART | - |
| dc.type.docType | Review | - |
| dc.description.journalClass | 1 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
| dc.subject.keywordPlus | ZINC-FINGER NUCLEASES | - |
| dc.subject.keywordPlus | HUMAN HEMATOPOIETIC STEM | - |
| dc.subject.keywordPlus | SITU GENETIC CORRECTION | - |
| dc.subject.keywordPlus | PATIENT-SPECIFIC IPSCS | - |
| dc.subject.keywordPlus | TAL EFFECTORS | - |
| dc.subject.keywordPlus | CORECEPTOR CCR5 | - |
| dc.subject.keywordPlus | CYSTIC-FIBROSIS | - |
| dc.subject.keywordPlus | DNA RECOGNITION | - |
| dc.subject.keywordPlus | MESSENGER-RNA | - |
| dc.subject.keywordPlus | T-CELLS | - |
| dc.subject.keywordAuthor | Zinc finger nucleases | - |
| dc.subject.keywordAuthor | Transcription activator-like effector nucleases | - |
| dc.subject.keywordAuthor | Clustered regularly interspaced short palindrome repeat associated system | - |
| dc.subject.keywordAuthor | Induced pluripotent stem cells | - |
| dc.subject.keywordAuthor | Hematopoietic stem cells | - |
| dc.identifier.url | https://link.springer.com/article/10.1007%2Fs12033-018-0072-9 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
